초록 ▼

Compounds of the following structure are described: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraceptio

Compounds of the following structure are described: wherein R1-R6, R16, m, V, W, X, Y, and Q are described herein, or a pharmaceutically acceptable salt, tautomer, metabolite or prodrug thereof. These compounds are useful for treating a variety of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus.

대표청구항 ▼

What is claimed is: 1. A compound of the structure: wherein: R1, R2, R3, R4, R5 and R6 are independently H, C1 to C10 alkyl,--(CH2)n-aryl,--(CH2)p--O--(CH2)n-aryl,--(CH2)nC(H)3-p(R7)p,--(CH2)nCOOR8, or--(CH2)p--O--R9; or R1, R2 or R3, R4 or R5, R6 are taken together to form a 3 to 6 membered cyc

What is claimed is: 1. A compound of the structure: wherein: R1, R2, R3, R4, R5 and R6 are independently H, C1 to C10 alkyl,--(CH2)n-aryl,--(CH2)p--O--(CH2)n-aryl,--(CH2)nC(H)3-p(R7)p,--(CH2)nCOOR8, or--(CH2)p--O--R9; or R1, R2 or R3, R4 or R5, R6 are taken together to form a 3 to 6 membered cycloalkyl ring; or when m is 0, R1 or R2 form a 5 to 7 membered cycloakyl ring with R5 or R6; or when m is 0, R1 or R2 form a 6-membered aryl ring with R5 or R6; R7 is halogen; R8 is C1 to C6 alkyl; R9 is H, C1 to C6 alkyl, or C1 to C3 perfluoroalkyl; W is O, NR10, or CR11R12; R10 is H, C1 to C6 alkyl, or (CH2)n-aryl; R11 and R12 are, independently, H, C1 to C6 alkyl, or--(CH2)n-aryl; or R11 or R12 form a double bond with either R5 or R6; V is O, S, or NR13; R13 is H, C1 to C6 alkyl,--(CH2)n-aryl,--(CH2)n--CN,--CO--(C1 to C6 alkyl),--CO--(CH2)n-aryl,--SO2--(C1 to C6 alkyl), or--SO2--(CH2)n-aryl; X is N or CR14; R14 is C1 to C6 alkyl,--(CH2)n-aryl,--(CH2)n--O--(CH2)n-alkyl,--(CH2)n--O--(CH2)n-aryl, halogen, hydroxy, C1 to C3 perfluoroalkyl, C1 to C3 perfluoroalkoxy or (CH2)n--CN; Y is O or S; R16 forms a two carbon saturated or unsaturated bond with Q to give a tricyclic ring system; Q is aryl, substituted aryl, heteroaryl, or substituted heteroaryl; m is 0 or 1; n is 0 to 3; p is 1 to 3; or a pharmaceutically acceptable salt thereof. 2. The compound according to claim 1, wherein: X is N; Y is S. 3. The compound according to claim 1, wherein: V is O; W is O; m is 0. 4. A compound according to claim 1, wherein: R1 and R2 are C1 to C10 alkyl; R5 and R6 are H. 5. The compound according to claim 1, wherein R16 forms a two carbon saturated bond with Q to provide a tricyclic ring system. 6. The compound according to claim 1, wherein Q is an aromatic carbon-based ring. 7. The compound according to claim 1, wherein Q is an optionally substituted phenyl ring. 8. The compound according to claim 7, wherein said phenyl ring contains a CN substituent. 9. The compound according to claim 1 of the structure: wherein: R15 is (CH2)nCN, halogen, NO2,--C(NH2)═NOH, C1 to C3 perfluoroalkyl, C1 to C3 perfluoroalkoxy,--O(C1 to C4 alkyl),--O(C1 to C4 substituted alkyl),--SO2--(C1 to C4 alkyl),--SO2--(C1 to C4 substituted alkyl),--CO--(C1 to C4 alkyl),--CO--(C1 to C4 substituted alkyl), C1 to C4 alkyl, C1 to C4 substituted alkyl,--O--(CH2)n-aryl,--COO--(C1 to C4 alkyl),--COO--(C1 to C4 substituted alkyl),--CONH--(C1 to C3 alkyl),--CON--(C1 to C3 alkyl)2, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; and q is 1 to 4. 10. The compound according to claim 1 of the structure: wherein: R15 is (CH2)nCN, halogen, NO2,--C(NH2)═NOH, C1 to C3 perfluoroalkyl, C1 to C3 perfluoroalkoxy,--O(C1 to C4 alkyl),--O(C1 to C4 substituted alkyl),--SO2--(C1 to C4 alkyl),--SO2--(C1 to C4 substituted alkyl),--CO--(C1 to C4 alkyl),--CO--(C1 to C4 substituted alkyl), C1 to C4 alkyl, C1 to C4 substituted alkyl,--O--(CH2)n-aryl,--COO--(C1 to C4 alkyl),--COO--(C1 to C4 substituted alkyl),--CONH--(C1 to C3 alkyl),--CON--(C1 to C3 alkyl)2, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; and q is 1 to 4. 11. The compound according to claim 1 of the structure: wherein: R15 is (CH2)nCN, halogen, NO2,--C(NH2)═NOH, C1 to C3 perfluoroalkyl, C1 to C3 perfluoroalkoxy,--O(C1 to C4 alkyl),--O(C1 to C4 substituted alkyl),--SO2--(C1 to C4 alkyl),--SO2--(C1 to C4 substituted alkyl),--CO--(C1 to C4 alkyl),--CO--(C1 to C4 substituted alkyl), C1 to C4 alkyl, C1 to C4 substituted alkyl,--O--(CH2)n-aryl,--COO--(C1 to C4 alkyl),--COO--(C1 to C4 substituted alkyl),--CONH--(C1 to C3 alkyl),--CON--(C1 to C3 alkyl)2, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; and q is 1 to 4. 12. The compound according to claim 1 of the structure: wherein: R15 is (CH2)nCN, halogen, NO2,--C(NH2)═NOH, C1 to C3 perfluoroalkyl, C1 to C3 perfluoroalkoxy,--O(C1 to C4 alkyl),--O(C1 to C4 substituted alkyl),--SO2--(C1 to C4 alkyl),--SO2--(C1 to C4 substituted alkyl),--CO--(C1 to C4 alkyl),--CO--(C1 to C4 substituted alkyl), C1 to C4 alkyl, C1 to C4 substituted alkyl,--O--(CH2)n-aryl,--COO--(C1 to C4 alkyl),--COO--(C1 to C4 substituted alkyl),--CONH--(C1 to C3 alkyl),--CON--(C1 to C3 alkyl)2, aryl, substituted aryl, heteroaryl, or substituted heteroaryl; and q is 1 to 4. 13. The compound according to claim 12, wherein R15 is CN, halogen, or NO2. 14. The compound according to claim 1, wherein R1, R2, R5, and R6 are independently H or C1 to C10 alkyl. 15. The compound according to claim 1, wherein R1 and R2 are taken together to form a carbon-based 3 to 6 membered saturated ring. 16. The compound according to claim 1 which is 2-(4,4-Dimethyl-2-oxo-1,3-oxazolidin-3-yl)-4,5-dihydronaphtho[1,2-d] [1,3]thiazole-7-carbonitrile, 2-(4,4-Diethyl-2-oxo-1,3-oxazolidin-3-yl)-4,5-dihydronaphtho[1,2-d] [1,3]thiazole-7-carbonitrile, or 2-(4,4-Dimethyl-2-oxo-1,3-oxazolidin-3-yl)naphtho[1,2-d] [1,3]thiazole-7-carbonitrile. 17. A compound of the structure: wherein: R1, R2, R5 and R6 are independently H, C1 to C10 alkyl,--(CH2)n-aryl,--(CH2)p--O--(CH2)n-aryl,--(CH2)nC(H)3-p(R7)p,--(CH2)nCOOR8, or--(CH2)p--O--R9; or R1, R2 or R5, R6 are taken together to form a 3 to 6 membered cycloalkyl ring; or R1 or R2 form a 5 to 7 membered cycloalkyl ring with R5 or R6; or R1 or R2 form a 6-membered aryl ring with R5 or R6; R7 is halogen; R8 is C1 to C6 alkyl; R9 is H, C1 to C6 alkyl, or C1 to C3 perfluoroalkyl; R15 is (CH2)nCN, halogen, NO2,--C(NH2)═NOH, C1 to C3 perfluoroalkyl, C1 to C3 perfluoroalkoxy,--O(C1 to C4 alkyl),--SO2--(C1 to C4 alkyl),--CO--(C1 to C4 alkyl), C1 to C4 alkyl,--O--(CH2)n-aryl,--COO--(C1 to C4 alkyl),--CONH--(C1 to C3 alkyl),--CON--(C1 to C3 alkyl)2, aryl, or heteroaryl; n is 0 to 3; p is 1 to 3; q is 1 to 4; or a pharmaceutically acceptable salt thereof. 18. A compound of the structure: wherein: R1 and R2 are independently H, C1 to C10 alkyl,--(CH2)n-aryl,--(CH2)p--O--(CH2)n-aryl,--(CH2)nC(H)3-p(R7)p,--(CH2)nCOOR8, or--(CH2)p--O--R9; R7 is halogen; R8 is C1 to C6 alkyl; R9 is H, C1 to C6 alkyl, or C1 to C3 perfluoroalkyl; R15 is (CH2)nCN, halogen, NO2,--C(NH2)═NOH, C1 to C3 perfluoroalkyl, C1 to C3 perfluoroalkoxy,--O(C1 to C4 alkyl),--SO2--(C1 to C4 alkyl),--CO--(C1 to C4 alkyl), C1 to C4 alkyl,--O--(CH2)n-aryl,--COO--(C1 to C4 alkyl),--CONH--(C1 to C3 alkyl),--CON--(C1 to C3 alkyl)2, aryl, or heteroaryl; q is 1 to 4; n is 0 to 3; p is 1 to 3; or a pharmaceutically acceptable salt thereof. 19. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.